drugset

drugset / Trial / NCT05580796

KSH01-R02-101 Solid Tumors

NCT05580796 ↗

Phase 0 Recruiting 50 enrolled TCRx Therapeutics Co.Ltd

NaSingle-groupOpen-labelTreatment

Summary

1. . safety and tolerance 2. . objective response rate

Timeline

Start: 2022-10-11
Primary completion: 2025-10-11
Completion: 2027-10-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KSH01	Cell therapy	—	—

Indications